Lincotek receives FDA 510(k) clearance for SportLinc Syndesmosis Device targeting orthopedic OEM market

Lincotek has obtained FDA 510(k) clearance (K252081) for its SportLinc Syndesmosis Device, a sterile, single-use implant designed to stabilize syndesmotic ankle trauma. The device features an ultra-high-molecular-weight polyethylene suture between two low-profile titanium alloy buttons, delivered preloaded in a sterile inserter instrument. The complete single-use kit includes a drill, drill guide, and tension handles, and can be used alongside plate fixation or as a standalone solution. Francesco Bucciotti, Head of Global Business and Business Development at Lincotek’s Medical Division, stated the company can bring products from concept to 510(k) approval in under one year, positioning SportLinc as a market-ready solution for orthopedic OEMs targeting sports injury applications.

This clearance is significant because it demonstrates a mature contract manufacturing model in additive medical devices, where Lincotek provides not just production capacity but a fully cleared, private-label-ready implant platform. The device is available for OEM private labeling and can serve as a predicate device, enabling partners to accelerate their own regulatory pathways. This aligns with the broader trend in medical-dental AM where service bureaus and contract manufacturers are moving up the value chain from component production to full device ownership and regulatory submission. Lincotek is now pursuing CE Mark certification to extend into European markets, reinforcing its strategy of supporting orthopedic OEMs across major regulatory jurisdictions. The company operates a state-of-the-art additive production facility, and this clearance validates its ability to combine design, manufacturing, and regulatory expertise into a single commercial package.

For Lincotek, the practical next step is converting this regulatory asset into signed OEM supply agreements and demonstrating repeatable production at scale. The device’s private-label and predicate-device positioning lowers the barrier for orthopedic companies to enter the syndesmosis fixation market without internal R&D investment. The real test will be whether Lincotek can sustain the sub-one-year concept-to-clearance timeline across a pipeline of additional implant platforms, which would differentiate it from competitors who offer only manufacturing services without regulatory support.